Abstract: The present application relates to substituted indazoles, to the use thereof alone or in combinations for treatment and/or prophylaxis of autoimmune disorders, and to the use thereof for production of medicaments for treatment and/or prophylaxis of autoimmune disorders, especially for treatment and/or prophylaxis of arthritides (especially psoriatic arthritis, rheumatoid arthritis, Bekhterev's disease, reactive arthritis, systematic juvenile idiopathic arthritis), systematic lupus erythematosus, multiple sclerosis, psoriasis, atopic dermatitis, allergic eczema and chronic-inflammatory bowel disorders (especially Crohn's disease and ulcerative colitis).
Type:
Grant
Filed:
February 16, 2022
Date of Patent:
May 28, 2024
Assignee:
Bayer Pharma Aktiengesellschaft
Inventors:
Alexandra Rausch, Stefan Joachim Jodl, Jörn Krätzschmar, Ulrich Bothe, Nicole Schmidt
Abstract: A ethyl 2-[9-(6-chloro-2-hydroxyquinolin-3-yl)-3,6-diphenyl-1,8-dioxo-3,4,9,10-tetrahydroacridine-10-yl]-acetate compound, its synthesis, and its use as an antimicrobial agent.
Type:
Grant
Filed:
November 2, 2023
Date of Patent:
May 21, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
Abstract: An object of the present invention is to provide a compound that has a specific chemical structure having an activation effect on SIRT6 and is useful as an active component for preventing and treating inflammatory diseases, and the present invention relates to a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof, where each symbol in Formula (1) has the same definition as that described in the specification.
Abstract: The present invention relates to a novel p62 ligand compound, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for preventing or treating proteinopathies comprising the same as an active ingredient. The p62 ligand compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various proteinopathies by activating autophagy in cells and thus selectively eliminating in vivo proteins, organelles and aggregates.
Type:
Grant
Filed:
July 24, 2019
Date of Patent:
May 14, 2024
Assignee:
AUTOTAC INC.
Inventors:
Yong Tae Kwon, Chang Hoon Ji, Srinivasrao Ganipisetti, Hee Yeon Kim, Su Ran Mun, Chan Hoon Jung, Eui Jung Jung, Ki Woon Sung
Abstract: Provided herein are novel lipase inhibitors and methods for using the same to treat inflammation, multisystem organ failure, necrotic pancreatic acinar cell death, acute pancreatitis, sepsis (e.g., culture negative sepsis), burns, and acne. For example, provided herein are two novel lipase inhibitors useful in the methods described herein: or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
March 3, 2023
Date of Patent:
May 7, 2024
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Vijay P. Singh, Sampath-Kumar Anandan, Kevin Greenman, Zeeshan Kamal
Abstract: A 3-cyano-2-ethoxy-9-(2-nitrobenzylidene)-4-(2-nitrophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine compound, its synthesis, and its use as an antimicrobial agent.
Type:
Grant
Filed:
December 8, 2023
Date of Patent:
May 7, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Ibrahim Abdelhamid Mohamed Elshaer, Antar Ahmed Abdelhamid Ahmed
Abstract: To achieve a method for producing a carbonic ester at a high yield by a simple process while suppressing formation of by-products, for example, a method for producing an aliphatic carbonic ester. The above problem is solved by a method for producing a carbonic ester, the method including a carbonic ester formation reaction in which an alcohol and carbon dioxide are reacted in the presence of an aromatic nitrile compound and a catalyst, wherein the water content in the alcohol used in the carbonic ester formation reaction is 0.10% by mass or less.
Abstract: A 7-(4-fluorobenzylidene)-4-(4-fluorophenyl)-2-methoxy-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile compound, its synthesis, and its use as an antimicrobial agent.
Type:
Grant
Filed:
December 8, 2023
Date of Patent:
April 30, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Mohamed Gouda Mahmoud, Hany Mohamed Abd El-Latef Ahmed, Mai Mostafa Khalaf Ali, Saad Shaaban, Antar Ahmed Abdelhamid Ahmed
Abstract: An 9-(2-hydroxyquinoline-3-yl)-10-[3-(dimethylamino)propyl]-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.
Type:
Grant
Filed:
November 3, 2023
Date of Patent:
April 30, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).
Type:
Grant
Filed:
March 1, 2021
Date of Patent:
April 23, 2024
Assignee:
UNM RAINFOREST INNOVATIONS
Inventors:
Eric R. Prossnitz, Geetanjali Sharma, Matthias Barton, Matthias R. Meyer
Abstract: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed.
Abstract: The present invention relates to compound of formula (I), wherein R1 is chloro, bromo iodo or a brosylate group. The present invention also relates to methods of making this compound and its use in carrying out organic transformations.
Abstract: A N?-({[(5-phenyl-1,3,4-oxadiazol-2-yl)sulfanyl]acetyl}oxy)benzenecarboximidamide compound, its synthesis, and its use as an antimicrobial agent.
Type:
Grant
Filed:
October 13, 2023
Date of Patent:
April 16, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
Abstract: An acetylsalicylic acid derivative and an application thereof. The present disclosure relates to the field of chemical pharmaceuticals, and in particular, to a compound shown in formula (I) or pharmaceutically acceptable salts thereof.
Abstract: Selective small molecule regulators of GIRK potassium channels are provided, which are effective in treatment of post-traumatic stress disorder and other medical conditions.
Type:
Grant
Filed:
June 11, 2019
Date of Patent:
April 9, 2024
Assignees:
Northeastern University, Indiana University Research and Technology Corporation
Inventors:
Ganeshsingh A. Thakur, Diomedes E. Logothetis, Lucas Cantwell, Yu Xu, Anantha Shekhar
Abstract: Provided is a method for preventing or treating a wound or scar comprising administering to a subject in need thereof a pharmaceutical composition comprising benzbromarone as an active ingredient, wherein benzbromarone inhibits the function of heat shock protein 47 (HSP47), or inhibits the accumulation of collagen by reducing collagen overproduction cells.
Abstract: A crystalline form I of 1,4-BIS[1,2-BENZISOSELENAZOL-3(2H)-one]-butane has characteristic peaks at 2? angles of 6.17±0.20°, 12.28±0.20°, 18.44±0.20°, 25.92±0.20° and 30.95±0.20° by X-ray powder diffraction using Cu-K? radiation.
Abstract: Diphosphate salts of N2-(2-ethoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-6-methyl-N8-neopentylpyrido[3,4-d]pyrimidine-2,8-diamine, and crystalline forms thereof, processes for the preparation of the new salt forms; and their use as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer.
Type:
Grant
Filed:
June 6, 2019
Date of Patent:
April 2, 2024
Assignee:
CRT Pioneer Fund LP
Inventors:
Julian S. Northen, John Mykytiuk, Gillian Moore
Abstract: A 1-cyclopropyl-6-fluoro-4-oxo-7-(4-((5-oxo-2-phenyl-4-(quinolin-2-ylmethylene)-4,5-dihydro-1H-imidazol-1-yl)methyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid compound, its synthesis, and its use as an anticancer and/or anti-inflammatory agent.
Type:
Grant
Filed:
September 21, 2023
Date of Patent:
April 2, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.
Type:
Grant
Filed:
October 12, 2021
Date of Patent:
March 26, 2024
Assignee:
MERCK PATENT GMBH
Inventors:
Dieter Dorsch, Mathilde Muzerelle, Lars Burgdorf, Margarita Wucherer-Plietker, Paul Czodrowski, Christina Esdar, Christos Tsaklakidis